Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains, as well as collaboration with GC Cell. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc. more
Time Frame | CKPT | Sector | S&P500 |
---|---|---|---|
1-Week Return | -12.83% | -2.27% | -0.57% |
1-Month Return | 1.38% | -3.96% | 1.21% |
3-Month Return | 59.57% | -9.7% | 7.57% |
6-Month Return | 79.02% | -3.37% | 11.45% |
1-Year Return | 14.69% | 3.71% | 28.48% |
3-Year Return | -87.64% | 3.8% | 29.52% |
5-Year Return | -71.1% | 39.78% | 90.66% |
10-Year Return | -92.66% | 106.91% | 203.75% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 1.71M | 1.07M | 268.00K | 192.00K | 103.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":62.59,"profit":true},{"date":"2021-12-31","value":15.69,"profit":true},{"date":"2022-12-31","value":11.24,"profit":true},{"date":"2023-12-31","value":6.03,"profit":true}] |
Cost of Revenue | 19.32M | 16.35M | 48.45M | 49.83M | 43.57M | [{"date":"2019-12-31","value":38.79,"profit":true},{"date":"2020-12-31","value":32.82,"profit":true},{"date":"2021-12-31","value":97.25,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":87.44,"profit":true}] |
Gross Profit | 1.71M | 1.07M | 268.00K | (49.63M) | (43.46M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":62.59,"profit":true},{"date":"2021-12-31","value":15.69,"profit":true},{"date":"2022-12-31","value":-2905.91,"profit":false},{"date":"2023-12-31","value":-2544.67,"profit":false}] |
Gross Margin | 100.00% | 100.00% | 100.00% | (25850.52%) | (42197.09%) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-25850.52,"profit":false},{"date":"2023-12-31","value":-42197.09,"profit":false}] |
Operating Expenses | 26.56M | 24.27M | 56.99M | 58.52M | 52.25M | [{"date":"2019-12-31","value":45.38,"profit":true},{"date":"2020-12-31","value":41.47,"profit":true},{"date":"2021-12-31","value":97.38,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":89.28,"profit":true}] |
Operating Income | (24.85M) | (23.20M) | (56.72M) | (58.33M) | (52.15M) | [{"date":"2019-12-31","value":-2485000000,"profit":false},{"date":"2020-12-31","value":-2320100000,"profit":false},{"date":"2021-12-31","value":-5672300000,"profit":false},{"date":"2022-12-31","value":-5833300000,"profit":false},{"date":"2023-12-31","value":-5214800000,"profit":false}] |
Total Non-Operating Income/Expense | 272.00K | 240.00K | 106.00K | (4.13M) | 455.00K | [{"date":"2019-12-31","value":59.78,"profit":true},{"date":"2020-12-31","value":52.75,"profit":true},{"date":"2021-12-31","value":23.3,"profit":true},{"date":"2022-12-31","value":-907.91,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (24.71M) | (23.08M) | (56.67M) | (62.62M) | (51.85M) | [{"date":"2019-12-31","value":-2471400000,"profit":false},{"date":"2020-12-31","value":-2308100000,"profit":false},{"date":"2021-12-31","value":-5667000000,"profit":false},{"date":"2022-12-31","value":-6262400000,"profit":false},{"date":"2023-12-31","value":-5184700000,"profit":false}] |
Income Taxes | (136.00K) | (120.00K) | (53.00K) | 4.29M | (167.90K) | [{"date":"2019-12-31","value":-3.17,"profit":false},{"date":"2020-12-31","value":-2.8,"profit":false},{"date":"2021-12-31","value":-1.24,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-3.91,"profit":false}] |
Income After Taxes | (24.58M) | (22.96M) | (56.62M) | (66.92M) | (51.68M) | [{"date":"2019-12-31","value":-2457800000,"profit":false},{"date":"2020-12-31","value":-2296100000,"profit":false},{"date":"2021-12-31","value":-5661700000,"profit":false},{"date":"2022-12-31","value":-6691500000,"profit":false},{"date":"2023-12-31","value":-5167910500,"profit":false}] |
Income From Continuous Operations | (24.71M) | (23.08M) | (56.67M) | (62.62M) | (53.74M) | [{"date":"2019-12-31","value":-2471400000,"profit":false},{"date":"2020-12-31","value":-2308100000,"profit":false},{"date":"2021-12-31","value":-5667000000,"profit":false},{"date":"2022-12-31","value":-6262400000,"profit":false},{"date":"2023-12-31","value":-5374100000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (24.58M) | (22.96M) | (56.62M) | (66.92M) | (51.85M) | [{"date":"2019-12-31","value":-2457800000,"profit":false},{"date":"2020-12-31","value":-2296100000,"profit":false},{"date":"2021-12-31","value":-5661700000,"profit":false},{"date":"2022-12-31","value":-6691500000,"profit":false},{"date":"2023-12-31","value":-5184700000,"profit":false}] |
EPS (Diluted) | (7.00) | (4.10) | (7.40) | (7.09) | (3.33) | [{"date":"2019-12-31","value":-700,"profit":false},{"date":"2020-12-31","value":-410,"profit":false},{"date":"2021-12-31","value":-740,"profit":false},{"date":"2022-12-31","value":-709,"profit":false},{"date":"2023-12-31","value":-333,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CKPT | |
---|---|
Cash Ratio | 0.26 |
Current Ratio | 0.29 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CKPT | |
---|---|
ROA (LTM) | -316.70% |
ROE (LTM) | -1220.38% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CKPT | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 3.43 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -2.43 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CKPT | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 2297.63 |
P/B | 8.56 |
Price/FCF | NM |
EV/R | 3713.03 |
EV/Ebitda | NM |
PEG | NM |
Checkpoint Therapeutics Inc (CKPT) share price today is $3.67
Yes, Indians can buy shares of Checkpoint Therapeutics Inc (CKPT) on Vested. To buy Checkpoint Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CKPT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Checkpoint Therapeutics Inc (CKPT) via the Vested app. You can start investing in Checkpoint Therapeutics Inc (CKPT) with a minimum investment of $1.
You can invest in shares of Checkpoint Therapeutics Inc (CKPT) via Vested in three simple steps:
The 52-week high price of Checkpoint Therapeutics Inc (CKPT) is $4.5. The 52-week low price of Checkpoint Therapeutics Inc (CKPT) is $1.36.
The price-to-earnings (P/E) ratio of Checkpoint Therapeutics Inc (CKPT) is
The price-to-book (P/B) ratio of Checkpoint Therapeutics Inc (CKPT) is 8.56
The dividend yield of Checkpoint Therapeutics Inc (CKPT) is 0.00%
The market capitalization of Checkpoint Therapeutics Inc (CKPT) is $194.35M
The stock symbol (or ticker) of Checkpoint Therapeutics Inc is CKPT